Core Viewpoint - The company has signed a long-term procurement agreement with Nanjing Mingji Hospital and Suzhou Mingji Hospital, committing to a minimum procurement amount of RMB 600 million over 96 months, which is expected to have a limited impact on the company's annual revenue [2][3][17]. Group 1: Contract Details - The contract stipulates that the total procurement amount from Mingji Hospitals will not be less than RMB 600 million over 96 months, with annual procurement expected to be less than 10% of the company's annual revenue [2][3]. - The contract includes provisions for price adjustments based on changes in procurement prices or project fees, with adjustments effective from the date of the announcement by the government or local procurement platform [2][12]. - The contract has been approved internally and does not constitute a related party transaction or a major asset restructuring [3][10]. Group 2: Parties Involved - Nanjing Mingji Hospital is a foreign-owned limited liability company with a registered capital of approximately USD 19.2 million, established in 2003, and is fully owned by Malaysian Mingji Bimoo Holdings [6][7]. - Suzhou Mingji Hospital is a non-wholly foreign-owned limited liability company with a registered capital of approximately RMB 601.98 million, established in 2004, with major shareholders being Mingji Bimoo Holdings and Suzhou Mingji Investment [8][9]. Group 3: Financial Impact - The contract is expected to positively impact the company's performance in 2026 and subsequent years, enhancing its profitability and competitive strength [17]. - The company emphasizes that the contract's execution will not lead to dependency on the hospitals for its business operations [18]. Group 4: Performance Forecast - The company anticipates a net loss of between RMB 36 million and RMB 25 million for the year 2025, a significant decline compared to the previous year's profit of approximately RMB 27.57 million [22][25]. - The expected loss is attributed to changes in the macro environment, competitive pricing pressures, and increased operational costs due to strategic investments in talent and technology [26].

Group 1 - The company is currently developing 3D printing materials primarily for the dental medical field, including resins for models, gums, and guides, as well as related printing equipment [2] - The company plans to actively explore the application of 3D printing zirconia technology in relevant medical fields [2]